Nano-Micro Letters,
Journal Year:
2025,
Volume and Issue:
17(1)
Published: Feb. 6, 2025
Abstract
The
use
of
microneedles
(MNs)
has
been
established
as
an
effective
transdermal
drug
delivery
strategy
that
extensively
deployed
for
treating
various
diseases,
including
skin
diseases.
MNs
can
surpass
the
constraints
conventional
methods
by
their
superior
safety
and
efficacy
through
precise
targeting,
while
simultaneously
enabling
painless
delivery.
Currently,
are
increasingly
used
carriers
delivery,
with
loading
insoluble
drugs
to
improve
treatment
efficiency
or
combining
bioactive
substances
construction
efficient
system
maximize
effects
substances.
preparation
diverse,
them
meet
requirements
most
applications.
emergence
addressed
shortcomings
associated
drugs,
expanded
applications
substances,
improved
in
clinical
practice.
This
review
summarizes
current
information
on
application
a
variety
such
psoriasis,
vitiligo,
alopecia,
hypertrophic
scarring,
atopic
dermatitis,
melanoma,
acne,
infections.
future
opportunities
diseases
also
discussed.
Despite
substantial
progress
vectors,
issues
low
poor
mechanical
strength
during
remain
main
challenges.
Therefore,
implementation
MNs-based
therapies
remains
limited,
highlighting
key
research.
Journal of Materials Chemistry B,
Journal Year:
2024,
Volume and Issue:
12(33), P. 8007 - 8032
Published: Jan. 1, 2024
Inflammatory
skin
diseases,
such
as
psoriasis
and
atopic
dermatitis,
pose
significant
health
challenges
due
to
their
long-lasting
nature,
potential
for
serious
complications,
risks,
which
requires
treatments
that
are
both
effective
exhibit
minimal
side
effects.
Hydrogels
offer
an
innovative
solution
biocompatibility,
tunability,
controlled
drug
delivery
capabilities,
enhanced
treatment
adherence
minimized
effects
risk.
This
review
explores
the
mechanisms
guide
design
of
hydrogel
therapeutic
platforms
from
multiple
perspectives,
focusing
on
components
hydrogels,
adjustable
physical
chemical
properties,
interactions
with
cells
drugs
underscore
clinical
potential.
We
also
examine
various
agents
dermatitis
can
be
integrated
into
including
traditional
drugs,
novel
compounds
targeting
oxidative
stress,
small
molecule
biologics,
emerging
therapies,
offering
insights
advantages.
Additionally,
we
trial
data
evaluate
effectiveness
safety
hydrogel-based
in
managing
under
complex
disease
conditions.
Lastly,
discuss
current
future
opportunities
therapeutics
treating
improving
barrier
penetration
developing
multifunctional
highlight
enhance
long-term
stability.
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(7), P. 845 - 845
Published: June 22, 2024
This
research
presents
the
efficacy
of
polymeric
microneedles
in
improving
transdermal
permeation
methotrexate
across
human
skin.
These
were
fabricated
from
PLGA
Expansorb
Molecular Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 17, 2025
This
investigation
aimed
to
enhance
transdermal
methotrexate
delivery
through
human
skin
by
employing
Dr.
Pen
microneedles
and
poly(d,l-lactide-co-glycolide)
acid
microparticles
formulated
from
eight
polymer
grades
(Expansorb
DLG
95-4A,
75-5A,
50-2A,
50-5A,
50-8A,
50-6P,
50-7P,
DLL
10-15A).
A
comprehensive
characterization
of
the
was
performed,
encompassing
various
parameters
such
as
size,
charge,
morphology,
microencapsulation
efficiency,
yield,
release
kinetics,
chemical
composition.
The
efficacy
in
disrupting
integrity
demonstrated
scanning
electron
microscopy,
dye
binding,
histological
examination,
confocal
laser
pore
size
analysis.
Microneedle-mediated
microporation
led
a
substantial
reduction
electrical
resistance
concomitant
increase
transepidermal
water
loss.
In
vitro
permeation
experiments
using
delivered
into
microporated
considerable
difference
among
groups.
Microneedle
treatment
significantly
amplified
cumulative
drug
delivery,
steady-state
flux,
diffusion
coefficient,
permeability
concentration
within
layers
while
concurrently
diminishing
lag
time
(p
<
0.05).
Furthermore,
robust
correlation
established
between
microparticle
properties
(cumulative
release,
rate,
encapsulation
efficiency)
deposition
skin.
conclusion,
synergistic
combination
PLGA
facilitated
enhanced
regulated
delivery.
Biomedicines,
Journal Year:
2025,
Volume and Issue:
13(4), P. 781 - 781
Published: March 23, 2025
Psoriasis
is
an
immune-related
disorder
that
marked
by
abnormal
thickening
of
the
skin,
rapid
multiplication
keratinocytes,
and
complex
interactions
between
immune
cells
affected
areas.
Although
psoriasis
cannot
currently
be
cured,
drugs
can
alleviate
symptoms
regulating
homeostasis
preventing
comorbidities.
There
are
many
types
to
treat
psoriasis:
small-molecule
drugs,
including
corticosteroids;
retinoids;
vitamin
D
analogs;
immunosuppressants,
such
as
glucocorticoid
ointment,
tretinoin
cream,
methotrexate
tablets,
etc.
Macromolecular
biological
Certolizumab,
Secukinumab,
Guselkumab,
etc.,
include
monoclonal
antibodies
target
various
inflammatory
signaling
pathways.
Compared
with
traditional
therapies
offer
better
targeting
lower
systemic
side
effects,
but
their
high
costs
invasive
administration
modes
constrict
widespread
use.
Spesolimab
latest
agent
used
interleukin-36
receptor
(IL-36R)
approved
for
market
use,
which
significantly
reduces
risk
general
pustular
(GPP)
flare
84%.
Additionally,
there
several
agents
interleukin-23/T
helper
17
cell
pathway
have
already
entered
Phase
II
III
clinical
trials.
At
present,
first-line
therapeutic
strategy
mild
topical
administration.
Systemic
therapy
phototherapy
preferred
treating
moderate
severe
types.
However,
current
completely
meet
needs.
More
advanced
drug
delivery
systems
optimized
effects
bioavailability
required.
Nanocarriers
emerging
proteins,
nucleic
acids,
cell-based
therapies.
In
this
review,
we
analyze
status
therapeutics
discuss
novel
diverse
well
We
also
summarize
effectiveness
different
strategies.
